Phase Ii Study of Biweekly Gemcitabine Followed by Oxaliplatin and Simplified 48-H Infusion of 5-Fluorouracil/Leucovorin (Gofl) in Advanced Pancreatic Cancer [PDF]
, 2011 To evaluate the efficacy and safety profile of a triplet regimen consisting of gemcitabine, oxaliplatin, and infusional fluorouracil and leucovorin (LV) in advanced pancreatic carcinoma (APC).
CHANG, HUI-JU;HUANG, CHING-LUN;WANG, HSIU-PO;SHIAH, HER-SHYONG;CHANG, MING-CHU;JAN, CHANG-MING;CHEN, JEN-SHI;TIEN, YU-WEN;HWANG, TSANN-LONG;LIN, JAW-TOWN;CHENG, ANN-LII;WHANG-PENG, JACQUELINE;CHEN, LI-TZONG +1 more
core +1 more source
Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison
BMC Cancer, 2008 Background Recent meta-analyses have found a survival advantage with gemcitabine based combinations over single agent gemcitabine in patients with advanced pancreatic cancer.
Neoptolemos John P +5 more
doaj +1 more source
Use of low-dose combined therapy with gemcitabine and paclitaxel for advanced urothelial cancer patients with resistance to cisplatin-containing therapy: a retrospective analysis [PDF]
, 2012 Purpose The prognosis of patients with advanced and recurrent urothelial cancer (UC) is poor. Although cisplatin (CDDP)-containing chemotherapy is the most effective regimen in these patients, there is no other established chemotherapeutic regimen.
Tomohiro Matsuo +13 more
core +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Purpose Despite 5‐year survival rates of over 90% among children and adolescents/young adults (CAYAs) with classic Hodgkin lymphoma (cHL), 15%–20% relapse after frontline therapy. Prior analysis of frontline Children's Oncology Group (COG) clinical trials demonstrated that, despite similar rates of relapse, non‐Hispanic Black (NHB) and ...
Mallorie B. Heneghan +14 more
wiley +1 more source
Gemcitabine-Induced Pulmonary Toxicity: A Case Report of Pulmonary Veno-Occlusive Disease [PDF]
, 2015 Introduction Gemcitabine is a chemotherapeutic agent frequently used by for the treatment of several malignancies both in the adjuvant and metastatic setting.
Célia Turco +10 more
core +1 more source
Solid Pseudopapillary Neoplasm of the Pancreas in Children and Adolescents: Expert Recommendations
Pediatric Blood &Cancer, EarlyView.ABSTRACT Solid pseudopapillary neoplasm of the pancreas (SPN) is a rare low‐grade malignant exocrine pancreatic tumor, mostly discovered during the second decade of life in females, with a very good prognosis, provided microscopically complete surgical excision is achieved.
Sabine Irtan +18 more
wiley +1 more source
Gemcitabine functions epigenetically by inhibiting repair mediated DNA demethylation.
PLoS ONE, 2010 Gemcitabine is a cytotoxic cytidine analog, which is widely used in anti-cancer therapy. One mechanism by which gemcitabine acts is by inhibiting nucleotide excision repair (NER).
Andrea Schäfer +4 more
doaj +1 more source
Cancer Medicine, 2023 Background This study aimed to clarify the treatment patterns of pancreatic cancer patients receiving systemic chemotherapy in Japan and to estimate the direct medical costs in actual practice.
Yuki Takumoto +3 more
doaj +1 more source
The Role of Chemotherapy in Pediatric Myoepithelial Carcinoma: A Systematic Review of the Literature
Pediatric Blood &Cancer, EarlyView.ABSTRACT Myoepithelial carcinoma (MEC) in pediatric patients is a rare and aggressive malignancy characterized by heterogeneous morphology and variable molecular features. The optimal role of chemotherapy remains unclear. We conducted a systematic review according to PRISMA 2020 guidelines to evaluate chemotherapy in pediatric and young‐adult patients ...
Marco Salvi +7 more
wiley +1 more source
Cell Death and Disease, 2021 Gemcitabine is the first-line chemotherapy drug for cholangiocarcinoma (CCA), but acquired resistance has been frequently observed in CCA patients. To search for potential long noncoding RNAs (lncRNAs) involved in gemcitabine resistance, two gemcitabine ...
Min Lu +6 more
doaj +1 more source